home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9409d.zip
/
M9490600.TXT
< prev
next >
Wrap
Text File
|
1994-09-24
|
3KB
|
41 lines
Document 0600
DOCN M9490600
TI Treatment of coccidioidomycosis with SCH 39304.
DT 9411
AU Hostetler JS; Catanzaro A; Stevens DA; Graybill JR; Sharkey PK; Larsen
RA; Tucker RM; al-Haidary AD; Rinaldi MG; Cloud GA; et al; Department of
Medicine, Santa Clara Valley Medical Center, San; Jose, CA 95128-2699.
SO J Med Vet Mycol. 1994;32(2):105-14. Unique Identifier : AIDSLINE
MED/94343183
AB A new oral triazole antifungal, SCH 39304, was administered to 54
patients with progressive infections due to Coccidioides immitis from
six collaborating centers. Patients were grouped according to site of
infection including chronic pulmonary (25), bone/joint (17) and
skin/soft tissue (12). The median age was 40 years; 83% were male, 52%
white, 13% HIV-infected and 35% had failed previous therapy. The
majority of patients were treated with either 100 mg or 200 mg day-1.
One patient on renal dialysis received 300 mg day-1. Baseline
abnormalities were reassessed for evidence of efficacy every 4 months
and expressed in a standardized scoring system. Cumulative overall
response rates at 4, 8 and 12 months were 7%, 36% and 66% respectively.
Twelve month response rates by disease were 77% (pulmonary), 62%
(skin/soft tissue) and 31% (bone/joint). Fifteen patients failed therapy
although seven of these were still on treatment when the study was
discontinued. Two failed due to toxicity. Possible symptoms or signs of
toxicity occurred in 24 (44%) patients and were generally mild. SCH
39304 is an effective and well tolerated therapy for progressive forms
of coccidioidomycosis.
DE Administration, Oral Adult Aged Aged, 80 and over Antifungal
Agents/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/ PHARMACOKINETICS
Coccidioidomycosis/*DRUG THERAPY Dermatomycoses/*DRUG THERAPY Drug
Administration Schedule Female Human HIV
Infections/COMPLICATIONS/DRUG THERAPY Joint Diseases/*DRUG THERAPY
Lung Diseases, Fungal/*DRUG THERAPY Male Middle Age Support, Non-U.S.
Gov't Support, U.S. Gov't, Non-P.H.S. Support, U.S. Gov't, P.H.S.
Treatment Outcome Triazoles/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/
PHARMACOKINETICS CLINICAL TRIAL JOURNAL ARTICLE MULTICENTER STUDY
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).